54396-39-3

Basic information

• Product Name: benzyl 3-(benzyloxy)benzoate
• Synonyms: benzyl 3-(benzyloxy)benzoate
• CAS NO: 54396-39-3
• Molecular Formula: C₂₁H₁₈O₃
• Molecular Weight: 318.36582
• Mol File: 54396-39-3.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: benzyl 3-(benzyloxy)benzoate(CAS DataBase Reference)
• NIST Chemistry Reference: benzyl 3-(benzyloxy)benzoate(54396-39-3)
• EPA Substance Registry System: benzyl 3-(benzyloxy)benzoate(54396-39-3)

Safety Data

• Hazardous Substances Data: 54396-39-3(Hazardous Substances Data)

Upstream product

• 500-32-3 N-benzyl-N,N-dimethyl-anilinium; dimethylphenylbenzylammonium hydroxide 
• 99-06-9 3-Carboxyphenol 
• 100-39-0 benzyl bromide 

Downstream Products

• 69026-14-8 3-benzyloxybenzoic acid 
• 1310328-54-1 3-benzyloxy-benzoic acid 3-hydroxy-2,2-dimethyl-chroman-7-yl ester 

Relevant articles and documents

How Many O-Donor Groups in Enterobactin Does It Take to Bind a Metal Cation?

The E. coli siderophore enterobactin, the strongest FeIII chelator known to date, forms hexacoordinate complexes with SiIV, GeIV, and TiIV. Synthetic protocols have been developed to prepare non-symmetric entero

HIF-1α inhibitors: Synthesis and biological evaluation of novel moracin O and P analogues

The natural products moracins O and P exhibited potent in vitro inhibitory activity against hypoxia-inducible factor (HIF-1), which is a key mediator during adaptation of cancer cells to tumour hypoxia. Systematic variations of the structures of benzofuran type moracins were made and structure-activity relationship analysis showed the importance of the 2-arylbenzofuran ring and the (R)-configuration of the core scaffold. Further evaluation of the representative compound 5 showed its inhibitory effect on HIF-1α protein accumulation and target gene expression under hypoxia.

COMPOSITIONS AND METHODS FOR GLUCOSE TRANSPORT INHIBITION

Glucose deprivation is an attractive strategy in cancer research and treatment. Cancer cells upregulate glucose uptake and metabolism for maintaining accelerated growth and proliferation rates. Specifically blocking these processes is likely to provide new insights to the role of glucose transport and metabolism in tumorigenesis, as well as in apoptosis. As solid tumors outgrow the surrounding vasculature, they encounter microenvironments with a limited supply of nutrients leading to a glucose deprived environment in some regions of the tumor. Cancer cells living in the glucose deprived environment undergo changes to prevent glucose deprivation-induced apoptosis. Knowing how cancer cells evade apoptosis induction is also likely to yield valuable information and knowledge of how to overcome the resistance to apoptosis induction in cancer cells. Disclosed herein are novel anticancer compounds that inhibit basal glucose transport, resulting in tumor suppression and new methods for the study of glucose deprivation in animal cancer research.

Novel inhibitors of basal glucose transport as potential anticancer agents

Cancer cells commonly show increased levels of glucose uptake and dependence. A potential strategy for the treatment of cancer may be the inhibition of basal glucose transport. We report here the synthesis of a small library of polyphenolic esters that inhibit basal glucose transport in H1299 lung and other cancer cells. These basal glucose transport inhibitors also inhibit cancer cell growth in H1299 cells, and these two activities appear to be correlated.